Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

Author： Ferrusi Ilia L   Marshall Deborah A   Kulin Nathalie A   Leighl Natasha B   Phillips Kathryn A  

Publisher： Future Medicine

ISSN： 1741-0541

Source： Personalized Medicine, Vol.6, Iss.2, 2009-03, pp. : 193-215

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment

By Hubalek Michael  

Wiener Medizinische Wochenschrift, Vol. 160, Iss. 19-20, 2010-11 ,pp. : 506-512

Springer Publishing Company

Access to resources Recommend Favorite

Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

By Santini Daniele   Vincenzi Bruno   Tonini Giuseppe  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite

Re-Evaluation of HER2 Status in Metastatic Breast Cancer and Tumor-Marker Guided Therapy with Vinorelbine and Trastuzumab

By  

Oncology Research and Treatment, Vol. 28, Iss. 2, 2005-02 ,pp. : 95-97

Karger

Access to resources Recommend Favorite